Nanoparticles as carriers for nasal vaccine delivery

Expert Review of Vaccines

Volumn 4, Issue 2, 2005, Pages 185-196

  Köping Höggård, Magnus ^a   Sánchez, Alejandro ^a   Alonso, María José ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chirosan; DNA; Mucosal; Nanoparticles; Nasal; PLA; PLGA; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM; ANTIGEN; BETA GALACTOSIDASE; CHITIN DERIVATIVE; CHITOSAN; COPOLYMER; DNA VACCINE; DRUG CARRIER; GLUCOSAMINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; LIPID; LIPOSOME; MACROGOL; MICROSPHERE; N ACETYLGLUCOSAMINE; NANOPARTICLE; OVALBUMIN; PLASMID DNA; POLOXAMER DERIVATIVE; POLOXAMINE DERIVATIVE; POLYESTER; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYOXYETHYLENE; POLYSACCHARIDE; POLYSTYRENE; POLYVINYL ALCOHOL; POVIDONE; PROTEIN VP1; SURFACTANT; TETANUS TOXOID; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG; VACCINE; VIROSOME;

ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIODEGRADABILITY; CHEMICAL COMPOSITION; COMPLEX FORMATION; CROSS LINKING; CYTOTOXIC T LYMPHOCYTE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA VACCINATION; MACROMOLECULE; MICROENCAPSULATION; MOLECULAR INTERACTION; MOLECULAR SIZE; MUCOSAL IMMUNITY; NANOTECHNOLOGY; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK BENEFIT ANALYSIS; SURFACE PROPERTY; TECHNIQUE; TH2 CELL; VACCINATION;

ADMINISTRATION, INTRANASAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; VACCINES;

EID: 17144431433     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.2.185     Document Type: Review

References (67)

1. Clements CJ, Aguado MT, Jodar L. Technologies to improve immunisation safety. Drug Safety 24, 1019-1026 (2001).
2. Czerkinsky C, Prince SJ, Michalek SM et al. IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc. Natl. Acad. Sci. USA 84, 2449-2453 (1987).
3. McDermont MR, Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory and genital tissues. J. Immunol. 122, 1892-1898 (1979).
4. Reveneau N, Alonso S, Jacob-Dubuisson F, Mercenier A, Locht C. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine 20, 926-933 (2001).
5. Beyer WE, Palache AM, De Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20, 1340-1353 (2002).
6. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm. Res. 19, 715-728 (2002).
7. Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv. Drug Deliv. Rev. 51, 127-141 (2001).
8. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52, 139-144 (2001).
9. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411-430 (2005).
10. Jung T, Kamm W, Breitenbach A et al. Tetanus toxoid-loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18, 352-360 (2001). Demonstrates the effect of particle size on the efficiency of modified polyester particles for mucosal immunization.
11. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J. Control. Rel. 78, 15-24 (2002).
12. Vila A, Sánchez A, Pérez C, Alonso MJ. PLA-PEG nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA. Polym. Adv. Tech. 13, 851-858 (2002).
13. Vila A, Sanchez A, Evora C et al. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol Med. Summer 17, 174-185 (2004).
14. Vila A, Gill H, McCallion O, Alonso MJ. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Rel. 98, 231-244 (2004). Shows for the first time the effect of the particle size and also of a polyethylene glycol (PEG) coating on the interaction and transport of nanoparticles across the nasal mucosa.
15. Vila A, Sanchez A, Janes K et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57, 123-131 (2004).
16. Kersten G, Hirschberg H. Antigen delivery systems. Expert Rev. Vaccines 3, 453-462 (2004).
17. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev. 51, 149-159 (2001).
18. Sjolander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 19, 2661-2665 (2001).
19. Somavarapu S, Alpar HO, Song CYS. Biodegradable nanoparticles in nasal vaccine delivery: effect of particle size and loading. Proc. Int. Symp. Control. Rel. Bioact. Mater. 25, 645-646 (1998).
20. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14, 259-266 (1997). Concludes that the uptake by and translocation from the intestinal mucosa of small particles is a normal occurrence.
21. Almeida AJ, Alpar HO, Brown MR. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J. Pharm. Pharmacol. 45, 198-203 (1993). Highlights for the first time the potential of poly(lactide-co- glycolide) nanoparticles as carriers for nasal vaccine delivery.
22. Tobío M, Alonso MJ. Study of the inactivation process of the tetanus toxoid in contact with PLGA degrading microspheres. STP Pharm. Sci. 8, 303-310 (1998).
23. Sanchez A, Gupta RK, Alonso MJ, Siber GR, Langer R. Pulsed controlled release system for potential use in vaccine delivery. J. Pharm. Sci. 85, 547-552 (1996).
24. Sanchez A, Villamayor B, Guo Y, McIver J, Alonso MJ. Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres. Int. J. Pharm. 185, 255-266 (1999).
25. Tobio M, Schwendeman SP, Guo Y et al. Improved immunogenicity of a core-coated tetanus toxoid delivery system. Vaccine 18, 618-622 (2000).
26. Tobio M, Nolley J, Guo Y, McIver J, Alonso MJ. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm. Res. 16, 682-688 (1999).
27. Csaba N, Gonzalez L, Sanchez A, Alonso MJ. Design and characterisation of new nanoparticulate polymer blends for drug delivery. J. Biomater. Sci. Polym. Ed. 15, 1137-1151 (2004).
28. Csaba N, Caamaño P, Sánchez A, Domínguez F, Alonso MJ. PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: new carriers for gene delivery. Biomacromolecules 6, 271-278 (2005).
29. Walter E, Dreher D, Kok M et al. Hydrophilic poly(DL-lactide-co- glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control. Rel. 76, 149-168 (2001).
30. Hsu YY, Hao T, Hedley ML. Comparison of process parameters for microencapsulation of plasmid DNA in poly(D,L-lactic-co-glycolic) acid microspheres. J. Drug Target. 7, 313-323 (1999).
31. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as nasal protein delivery systems. Pharm. Res. 15, 270-275 (1998). Highlights the positive influence of a PEG coating for the transport of polyester nanoparticles across the nasal mucosa.
32. Tobío M, Sanchez A, Vila A et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surfaces B: Biointerfaces 18, 315-323 (2000).
33. Vila A, Sánchez A, Evora C et al. PLA-PEG particles as nasal protein carriers: the influence of particle size. Int. J. Pharm. (2005) (In Press).
34. Vila A, Gill H, McCallion O, Alonso MJ. PLA-PEG nanoparticles as nasal drug carriers: approaches to the modulation of the PEG coating. Proc. Int. Symp. Control. Rel. Bioact. Mater. (2003).
35. Ilium L, Church AE, Butterworth MD et al. Development of systems for targeting the regional lymph nodes for diagnostic imaging: in vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm. Res. 18, 640-645 (2001).
36. Calvo P, Remunan C, Vila-Jato JL, Alonso MJ. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron emulsions. Colloid. Polym. Sci. 275, 46-53 (1997).
37. Artursson P, Landmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361 (1994).
38. Borchard G, Luessen HL, De Boer GA et al. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption III: effects of chitosan glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Rel. 39, 131-138 (1996).
39. Hellermann GR, Mohapatra SS. Genetic therapy: on the brink of a new future. Genetic Vaccines Ther. 1, 1 (2003).
40. Perez C, Sanchez A, Putnam D et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control. Rel. 75, 211-224 (2001).
41. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78, 43-48 (1992).
42. Schipper NG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 13, 1686-1692 (1996).
43. Schipper NG, Olsson S, Hoogstraate JA et al. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 14, 923-929 (1997).
44. Schipper NG, Varum KM, Stenberg P et al. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 8, 335-343 (1999).
45. Arai K, Kinumaki T, Fujita T. Toxicity of chitosan. Bull. Tokai. Feg. Fish Res. Lab. 56, 89-95 (1968).
46. Hirano S, Seino H, Akiyama Y, Nonaka I. Biocompatibility of chitosan by oral and intravenous administration. Polym. Eng. Sci. 59, 897-901 (1989).
47. Seferian PG, Martinez ML. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 19, 661-668 (2000).
48. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 21, 671-674 (2004).
49. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16, 2039-2046 (1998).
50. McNeela EA, O'Connor D, Jabbal-Gill I et al. A mucosal vaccine against diphtheria: formulation of cross-reacting material (CRM(197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19, 1188-1198 (2000).
51. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81-96 (2001).
52. Illum L. Nasal drug delivery possibilities, problems and solutions. J. Control. Rel. 87, 187-198 (2003).
53. McNeela EA, Jabbal-Gill I, Illum L et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T-cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22, 909-914 (2004). Demonstrates the potential of chitosan powders for nasal vaccination in humans.
54. Baudner BC, Giuliani MM, Verhoef JC et al. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21, 3837-3844 (2003).
55. Jiang HL, Park IK, Shin NR et al. Controlled release of Bordetella bronchiseptica dermonecrotoxin (BBD) vaccine from BBD-loaded chitosan microspheres in vitro. Arch. Pharm. Res. 27, 346-350 (2004).
56. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 14, 1431-1436 (1997).
57. Calvo P, Remunan-López C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Pol. Sci. 63, 125-132 (1997).
58. MacLaughlin FC, Mumper RJ, Wang J et al. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J. Control. Rel. 56, 259-272 (1998).
59. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Med. 5, 387-391 (1999).
60. Koping-Hoggard M, Tubulekas I, Guan H et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 8, 1108-1121 (2001).
61. Koping-Hoggard M, Mel'nikova YS, Varum KM, Lindman B, Artursson P. Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo. J. Gene Med. 5, 130-141 (2003).
62. Koping-Hoggard M, Varum KM, Issa M et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther. 11, 1441-1452 (2004).
63. Chen J, Yang WL, Li G et al. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol. 10, 112-116 (2004).
64. Kumar M, Behera AK, Lockey RF et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 13, 1415-1425 (2002). Demonstrates the potential of chitosan nanosystems for nasal DNA vaccination.
65. Iqbal M, Lin W, Jabbal-Gill I et al. Nasal delivery of chitosan-DNA plasmid-expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21, 1478-1485 (2003).
66. Xu W, Shen Y, Jiang Z et al. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22, 3603-3612 (2004).
67. Kuper CF, Koornstra PJ, Hameleers DM et al. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13, 219-224 (1992).